drugset / Trial / NCT04510402

Phase I/II Trial of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects

NCT04510402

Phase 1/2 Unknown 50 enrolled Brigham and Women's Hospital 3M · collab
Non-randomizedParallel-groupOpen-labelPrevention

Summary

Title: Phase I/II Trial (Safety and Dosing) of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects: Summary: This study will evaluate in a PH I/II trial in healthy volunteers the safety and tolerability of PVP-I nasal swabs daily application. The intent is to follow with a PH III randomized controlled clinical trial to assess the capacity for PVP-I nasal swabs to mitigate the transmission of respiratory viruses specifically COVID 19.

Timeline

Start
2020-08
Primary completion
2021-02
Completion
2021-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Povidone-Iodine Other / unclassified Intranasal